acetic acid-(6-nitro-indan-1-yl ester) | 773055-98-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: acetic acid-(6-nitro-indan-1-yl ester)
• 英文别名: Essigsaeure-(6-nitro-indan-1-ylester)；(+/-)-6-Nitro-1-acetoxy-indan；(+/-)-(6-Nitro-indanyl-(1))-acetat；(6-nitro-2,3-dihydro-1H-inden-1-yl) acetate
• CAS: 773055-98-4
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: CDWPWNOJPCAUPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  acetic acid-(6-nitro-indan-1-yl ester) 在 palladium on activated charcoal 氢气 、 三氯氧磷 作用下， 生成
  参考文献：
  名称：

  M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: Serominic compounds

  摘要：

  Chronic low-dose treatment of rats with the psychomimetic drug, phencyclidine, induces regionally specific metabolic and neurochemical changes in the CNS that mirror those observed in the brains of schizophrenic patients. Recent evidence suggests that drugs targeting serotoninergic and muscarinic receptors, and in particular 5-HT7 antagonists and M-4 agonists, exert beneficial effects in this model of schizophrenia. Compounds that display this combined pattern of activity we refer to as serominic compounds. Based upon leads from natural product screening, we have designed and synthesised such serominic compounds, which are principally arylamidine derivatives of tetrahydroisoquinolines, and shown that they have the required serominic profile in ligand binding assays and show potential antipsychotic activity in functional assays. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.093
• 作为产物：
  描述：

  6-硝基-2,3-二氢-1-H-茚-1-醇 生成 acetic acid-(6-nitro-indan-1-yl ester)
  参考文献：
  名称：

  23. 5-硝基茚的合成

  摘要：

  DOI：

  10.1039/jr9470000095

文献信息

• [EN] COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE ANTAGONISTE DU RECEPTEUR DE LA SEROTONINE 5-HT17 ET UNE ACTIVITE AGONISTE DU RECEPTEUR MUSCARINIQUE M4 ET UTILISATION DE CES COMPOSES POUR LE TRAITEMENT DES TROUBLES PSYCHOTIQUES
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004087124A1

  公开（公告）日：2004-10-14

  The present invention relates to novel treatments for schizophrenia, based on the concept of identifying agents capable of selectively binding to the serotonin 5-HT7 and muscarinic M4 receptors and the use of such compounds in treating schizophrenia. The present invention also relates to novel amidine compounds for treating schizophrenia, a method of manufacturing such compounds, pharmaceutical formulations comprising said compounds, as well as medical uses and methods of treatment using said compounds.

  本发明涉及基于识别能够选择性结合到5-羟色胺5-HT7和肌碱M4受体的药剂，并将这类化合物用于治疗精神分裂症的新型治疗方法。本发明还涉及用于治疗精神分裂症的新型胺基化合物，一种制造这类化合物的方法，包含该化合物的药物配方，以及使用该化合物进行治疗的医疗用途和治疗方法。